Has Imad Dibo, MD received payments from drug or device companies?

Yes. Drug and device makers reported $295 in general payments to Imad Dibo, MD across 16 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Imad Dibo, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Imad Dibo, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Imad Dibo, MD

Infectious Disease · Lakeland, FLNPI 1558397687

Payments from drug & device makers

$295in general payments, 2019–2025

Across 16 payments — averaging $18.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Merck$67
AbbVie$62
Ferring Pharmaceuticals Inc.$32
Tetraphase Pharmaceuticals, Inc.$31
Johnson & Johnson$29
Melinta Therapeutics, LLC$20
plus $54 from 3 others

What the payments were for

Food & beverage$295100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Merck	4	$67
AbbVie	3	$62
Ferring Pharmaceuticals Inc.	1	$32
Tetraphase Pharmaceuticals, Inc.	2	$31
Johnson & Johnson	2	$29
Melinta Therapeutics, LLC	1	$20
Insmed, Inc.	1	$19
Gilead	1	$18
Astellas Pharma US Inc	1	$17

How this compares

$295 in reported general payments places this provider in the 35th percentile of 669 infectious disease providers in Florida.

See all infectious disease providers in Florida →

Medicare billing

Part B allowed, 2024

$108,568

Medicare patients

309

Services billed

1,176

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Linezolid	11	$3,708
Cefepime Hcl	18	$2,632
Doxycycline Hyclate	33	$999
Cephalexin	16	$637
Azithromycin	12	$394
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav	20	$342
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim	13	$253
Ciprofloxacin Hcl	17	$239
Triamcinolone Acetonide	21	$110

Paid to pharmacies, not to this prescriber.

Other infectious disease in Lakeland

Moti RamgopalFort Pierce$13.5M
Larry BushAtlantis$9.3M
Olayemi OsiyemiWest Palm Beach$8.8M
Charlotte-Paige RolleOrlando$6M
Edwin DejesusOrlando$5.9M
Dushyantha JayaweeraMiami$5.1M
Federico HinestrosaOrlando$5.1M
Godson OguchiOrange City$5M
Ammara MushtaqGainesville$2.7M
Efrain GarciaMiami$2.5M

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →